Investing for the long termIf you've got it, don't flaunt itJoin the NASDAQ Community today and get free, instant access to portfolios, stock ratings, real-time alerts, and more!Bank of America Merrill Lynch took action on Bristol-Myers Squibb Company ( BMY ) and on Pfizer Inc. ( PFE ).Bank of America Merrill Lynch has restored its rating of neutral on shares of Bristol-Myers Squibb, as reported by StreetInsider.com, and set a price target of $63 per share of the U.S. pharma stock. This represents a slim 0.8% upside from the current share price that is $62.52 on the New York Stock Exchange.The average target price is $ 63.43, and the recommendation rating is 2.4 out of 5.Bristol-Myers Squibb has a market capitalization of $102.33 billion, a price to book (P/B) ratio of 6.92, a price to earnings (P/E) ratio of 24.61 and a price to sales (P/S) ratio of 5.05.The stock gained 7% so far this year, and the share price is about 5.7% below the 52-week high of $66.10 per share. The 52-week low is $46.01 per share.Bristol-Myers Squibb is currently trading above the Peter Lynch Earnings line, so according to this metric of evaluation the stock looks overvalued at the moment.Concerning estimates on the company's earnings for next year and for the next five years, analysts foresee 8.3% growth and 10.86% annual growth.Bristol-Myers Squibb is capable of generating cash flow of more than $5 billion from its operations in one year's time and about half of this amount is used for the company' business growth purposes and for paying dividends. According to a ratio of 61.18% of Bristol-Myers Squibb's net earnings, the U.S. pharmaceutical company is paying out to its shareholders part of its free cash flow.Bristol-Myers Squibb currently distributes an annual dividend of $1.56 to the holders of the company - through quarterly payments of 39 cents - for a dividend yield of 2.54% versus a S&P 500 current dividend yield of 1.83%.The forward PE ratio is 19.38 and the EPS - as forecasted by analysts for full fiscal 2018 - is $3.25. This is an average figure as well as the EPS of $3 forecasted for full fiscal 2017.GuruFocus gives Bristol-Myers Squibb a financial strength rating of 7 out of 10 and a profitability & growth rating of 6 out of 10.Bank of America Merrill Lynch has also reintroduced a buy rating on shares of Pfizer Inc., as reported by StreetInsider.com, and set a price target of $40 per share, which represents an 11.6% upside from the current share price of $35.85.The average target price is $ 38.14, while the recommendation rating is 2.5 out of 5.Pfizer has a market capitalization of $213.69 billion, a price to book (P/B) ratio of 3.51, a price to earnings (P/E) ratio of 22.27 and a price to sales (P/S) ratio of 4.17.Pfizer gained 10% year to date and 12% over the last 52 weeks, while the 52-week range is $30.51 to- $36.78.Pfizer is currently trading above the Peter Lynch Earnings line, so according to this metric of evaluation the stock seems to be overvalued.In addition, analysts foresee 5.80% growth in Pfizer's earnings from full fiscal 2017 to full fiscal 2018 and an annual growth of 5.95% over the following five year period.In one-year's time, the American pharmaceutical corporation can generate operating cash flow of more than $15 billion and levered free cash flow of more than $13 billion.Pfizer currently distributes - according to a pay-out ratio of 77.78% of its net sales - an annual dividend of $1.28 per share to its shareholders, through quarterly payments of 32 cents. The dividend yield is 3.61%.The forward P/E ratio is 12.94. For full fiscal years 2017 and 2018, analysts forecast Pfizer will close the reporting periods with an EPS of $2.6 and $2.75, respectively.GuruFocus gives Pfizer a financial strength rating of 5 out of 10 and a profitability & growth rating of 8 out of 10.Disclosure: I have no positions in any stock mentioned in this article.This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
					You have selected to change your default setting for the Quote Search. This will now be your default target page;
					unless you change your configuration again, or you delete your
					cookies. Are you sure you want to change your settings?
Please disable your ad blocker (or update your settings to ensure that javascript and cookies are enabled), so that we can continue to provide you with the first-rate market news and data you've come to expect from us.